



Name of the Company changed as  
"Haleos Labs Limited"

## SMS Lifesciences India Limited

### Registered & Corporate Office :

Plot No. 19-III, Road No. 71,  
Opp. Bharatiya Vidya Bhavan Public School,  
Jubilee Hills, Hyderabad - 500 096, Telangana, INDIA.  
Tel : +91-040-6628 8888, Fax : +91-40-2355 1401  
CIN : L74930TG2006PLC050223  
Email : info@smslife.in, Website : www.smslife.in

**November 10, 2025**

To

**BSE Limited,**

Listing Department, P J Towers,  
Dalal Street,  
Mumbai – 400 001.

**Scrip code: 540679**

Through: BSE Listing Center

**National Stock Exchange of India Limited,**

Listing Department, "Exchange Plaza",  
Bandra-Kurla Complex, Bandra (E),  
Mumbai - 400 051.

**Trading Symbol: SMSLIFE**

Through: NEAPS Portal

### **SUB: OUTCOME OF THE 95<sup>TH</sup> BOARD MEETING.**

**Ref: Regulation 30 and 33 read with Part "A" of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/Madam,

With reference to the above-cited subject, we would like to inform you that the Board of Directors of the Company at its Meeting held today i.e. **November 10, 2025**, have *inter-alia* considered and approved the unaudited [Standalone & Consolidated] financial results for the quarter and half year ended September 30, 2025, as recommended by the Audit Committee.

In this regard, we are enclosing herewith a copy of the following:

Sl. No.	Particulars
1)	Unaudited financial results (Standalone & Consolidated) for the quarter and half year ended September 30, 2025, along with limited review report.
2)	Statement of Assets & Liabilities and Cash-flow statement.
3)	Related Party Transactions for the half year ended September 30, 2025.

The meeting of the Board commenced at **02.45 pm** and concluded at **4.15 pm**.

### **For Haleos Labs Limited**

(Formerly known as "SMS Lifesciences India Limited")

**Trupti Ranjan Mohanty**

Company Secretary



The Company's name has changed to "HALEOS LABS LIMITED" and we are currently in process of adopting the same in compliance with applicable regulatory requirements.

# HALEOS LABS LIMITED

(Formerly known as SMS Lifesciences India Limited)

(CIN: L74930TG2006PLC050223)

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee hills, Hyderabad - 500 096

Tel:+91-40-6628 8888, Fax:91-40-2355 1401, Email: info@smslife.in

## Standalone Statement of Un-audited Financial Results for the Quarter and Half year Ended 30th September, 2025

(Rs. In Lakhs)

S.No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue From Operations	7,784.35	7,904.27	7,849.62	15,688.63	16,506.68	33,337.10
2	Other Income	43.64	100.94	125.58	144.58	168.56	394.56
3	<b>Total Revenue</b>	<b>7,827.99</b>	<b>8,005.21</b>	<b>7,975.20</b>	<b>15,833.21</b>	<b>16,675.24</b>	<b>33,731.66</b>
4	<b>Expenses</b>						
	(a) Cost of Materials Consumed	4,160.07	3,363.81	3,759.74	7,523.88	8,234.66	16,443.48
	(b) Changes in Inventories	(435.89)	540.14	125.67	104.25	213.71	468.60
	(c) Manufacturing Expenses	1,458.20	1,403.78	1,261.64	2,861.99	2,655.42	5,554.59
	(d) Employee Benefits Expense	1,237.52	1,249.50	1,089.82	2,487.02	2,207.75	4,577.67
	(e) Finance Cost	150.51	173.27	192.46	323.78	408.34	788.07
	(f) Depreciation and Amortization Expense	268.30	263.45	257.07	531.75	507.09	1,025.55
	(g) Other Expenses	284.50	263.46	432.76	547.95	638.54	1,869.59
	<b>Total Expenses - (a to g)</b>	<b>7,123.21</b>	<b>7,257.41</b>	<b>7,119.16</b>	<b>14,380.63</b>	<b>14,865.51</b>	<b>30,727.55</b>
5	<b>Profit Before Tax (3-4)</b>	<b>704.78</b>	<b>747.80</b>	<b>856.04</b>	<b>1,452.58</b>	<b>1,809.73</b>	<b>3,004.11</b>
6	<b>Tax Expenses</b>						
	(1) (i) Current Tax	200.00	225.00	250.00	425.00	550.00	900.00
	(ii) Relating to Earlier Year	-	-	-	-	-	(18.87)
	(2) Deferred Tax	7.01	7.03	5.21	14.04	12.91	(14.10)
	<b>Total Tax Expenses</b>	<b>207.01</b>	<b>232.03</b>	<b>255.21</b>	<b>439.04</b>	<b>562.91</b>	<b>867.03</b>
7	<b>Net Profit / (Loss) for the Period (5-6)</b>	<b>497.77</b>	<b>515.77</b>	<b>600.83</b>	<b>1,013.54</b>	<b>1,246.82</b>	<b>2,137.08</b>
8	<b>Other Comprehensive Income (OCI):</b>						
	Items that will not be reclassified to profit or Loss:						
	Remeasurement of post-employment benefit obligations	1.23	1.17	(17.43)	2.39	(33.41)	4.25
	Income Tax effect on the above	0.36	0.34	(5.07)	0.70	(9.73)	1.24
		<b>0.87</b>	<b>0.83</b>	<b>(12.36)</b>	<b>1.70</b>	<b>(23.68)</b>	<b>3.01</b>
9	<b>Total Comprehensive Income for the period (7+8)</b>	<b>498.64</b>	<b>516.60</b>	<b>588.47</b>	<b>1,015.23</b>	<b>1,223.14</b>	<b>2,140.09</b>
10	Earnings Per Equity Share of Rs.10/- each Basic / Diluted (not annualised)	<b>16.46</b>	<b>17.06</b>	<b>19.87</b>	<b>33.52</b>	<b>41.24</b>	<b>70.69</b>
11	Paid-up equity share capital (Face Value of Rs.10/- each)	<b>302.33</b>	<b>302.33</b>	<b>302.33</b>	<b>302.33</b>	<b>302.33</b>	<b>302.33</b>
12	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year						19,415.22

For Haleos Labs Limited

TVSN Murthy  
Managing Director  
DIN: 00465198



# Standalone Audited Statement of Assets and Liabilities as at 30th September, 2025

(Rs.in Lakhs)

Sr. No.	Particulars	As at	As at
		30.09.2025 (Un Audited)	31.03.2025 (Audited)
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-Current Assets</b>		
	(a) Property, Plant and Equipment	14,446.49	14,841.33
	(b) Right-of-use Assets	146.26	177.59
	(c) Capital Work-in-Progress	838.92	39.60
	(d) Intangible Assets	3.33	4.43
	(e) Financial Assets:		
	(i) Investments	2,323.17	2,323.17
	(ii) Other Financial Assets	281.44	278.32
	(f) Other Non-Current Assets	678.18	387.73
	<b>Sub Total :Non-Current Assets</b>	<b>18,717.79</b>	<b>18,052.17</b>
<b>2</b>	<b>Current Assets</b>		
	(a) Inventories	5,644.35	6,058.39
	(b) Financial Assets		
	(i) Trade Receivables	5,743.27	6,452.63
	(ii) Cash and Cash Equivalents	41.22	40.13
	(iii) Bank Balances (Other than (ii) above)	103.18	100.52
	(c) Other Current Assets	4,940.25	5,110.49
	(d) Current Tax Asset (Net)	-	16.79
	<b>Sub Total : Current Assets</b>	<b>16,472.27</b>	<b>17,778.95</b>
	<b>TOTAL ASSETS</b>	<b>35,190.06</b>	<b>35,831.12</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Equity:</b>		
	(a) Equity Share Capital	302.33	302.33
	(b) Other Equity	20,385.10	19,415.22
	<b>Sub-Total -Shareholders' funds</b>	<b>20,687.43</b>	<b>19,717.55</b>
	<b>Liabilities:</b>		
<b>2</b>	<b>Non-Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	1,273.41	1,731.06
	(ii) Lease Liabilities	126.00	173.92
	(b) Provisions	438.68	419.68
	(c) Deferred Tax Liabilities (net)	1,374.13	1,359.39
	<b>Sub-Total -Non-Current Liabilities</b>	<b>3,212.22</b>	<b>3,684.05</b>
<b>3</b>	<b>Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	5,208.98	6,186.19
	(ii) Lease Liabilities	79.73	65.47
	(iii) Trade Payables:		
	(a) Dues to Micro & Small Enterprises	101.89	79.32
	(b) Dues to Creditors other than Micro & Small Enterprises	4,072.32	4,519.18
	(iv) Other Financial Liabilities	931.02	1,100.90
	(b) Provisions	170.40	159.40
	(c) Other Current Liabilities	532.23	319.06
	(d) Current Tax Liabilities (Net)	193.84	-
	<b>Sub-Total - Current Liabilities</b>	<b>11,290.41</b>	<b>12,429.52</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>35,190.06</b>	<b>35,831.12</b>

For Haleos Labs Limited

TVVSN Murthy  
Managing Director  
DIN: 00465198

**HALEOS LABS LIMITED**

(Formerly known as SMS Lifesciences India Limited)

**Standalone Statement of Cash Flow for the Half Year Ended 30th September, 2025.**

(All amounts in Indian Rupees, unless otherwise stated)

Particulars		For the Half Year ended 30th Sept, 2025	For the Year ended 31st March, 2025
<b>A</b>	<b>Cash Flow from Operating Activities</b>		
	Profit Before Income Tax	1,452.58	3,004.11
	<b>Adjustments for:</b>		
	Depreciation and amortisation expense	531.75	1,025.55
	Interest Income classified as Investing Cash Flow	(2.96)	(6.53)
	Allowance for Doubtful Debts	-	505.99
	Interest on Non Current Borrowings	105.17	310.17
	Provision for Employee Benefits	32.39	18.07
	Term Loan Processing Fee	1.52	3.54
	Loss on Sale of Assets	-	2.84
	Profit on Sale of Assets.	-	(5.94)
	Interest on Leased Premises	12.84	31.14
		<b>2,133.29</b>	<b>4,888.94</b>
	<b>Change in Operating Assets and Liabilities</b>		
	(Increase)/Decrease in Trade Receivables	709.36	(2,023.93)
	(Increase)/Decrease in Inventories	414.03	1,400.49
	Increase/(Decrease) in Trade Payables	(424.29)	(355.27)
	(Increase)/Decrease in Other Non Current Financial Assets	(3.12)	(7.52)
	(Increase)/Decrease in Other Non Current Asset	(290.46)	(116.18)
	(Increase)/Decrease in Other Current Financial Assets	-	(0.10)
	(Increase)/Decrease in Other Current Asset	170.24	(94.56)
	(Increase) Decrease in Prepaid Taxes	(14.38)	(140.03)
	Increase/(Decrease) in Other Current Financial Liabilities	(4.61)	128.04
	Increase/(Decrease) in Other Current Liabilities	213.17	(26.64)
		<b>769.95</b>	<b>(1,235.69)</b>
	<b>Cash generated from Operations</b>	<b>2,903.24</b>	<b>3,653.25</b>
	Income Tax Paid	(200.00)	(850.00)
	<b>Net Cash Inflow from Operating Activities "A"</b>	<b>2,703.24</b>	<b>2,803.25</b>
<b>B</b>	<b>Cash flows from Investing Activities</b>		
	Purchase for Property, Plant and Equipment	(1,065.67)	(1,408.65)
	Proceeds from sale of Property, Plant and Equipment	4.45	33.63
	Margin Money Deposits	(0.62)	(7.87)
	Interest Received on Margin Money Deposit	0.91	6.28
	<b>Net Cash Outflow from Investing Activities "B"</b>	<b>(1,060.92)</b>	<b>(1,376.61)</b>
<b>C</b>	<b>Cash flows from Financing Activities</b>		
	Proceeds from Long Term Borrowings	-	35.42
	Repayment of Long Term Borrowings	(580.29)	(1,364.86)
	Proceeds from Short Term Borrowings	(856.08)	370.25
	Repayment of Lease Liability	(33.66)	(61.86)
	Interest paid	(125.86)	(353.60)
	Repayment of Unsecured Loan	-	-
	Dividend paid to company's shareholders	(45.35)	(45.35)
	<b>Net Cash (Outflow) from Financing Activities "C"</b>	<b>(1,641.24)</b>	<b>(1,420.00)</b>
	<b>Net Increase (Decrease) in Cash and Cash Equivalents (A+B+C)</b>	<b>1.09</b>	<b>6.64</b>
	Cash and Cash Equivalents at the beginning of the Financial Year	40.13	33.49
	<b>Cash and Cash Equivalents at End of the Year</b>	<b>41.22</b>	<b>40.13</b>

For Haleos Labs Limited

TVVSN Murthy  
Managing Director  
of the Year 2024-25  
65198



**Notes:**

- 1 The above standalone Financial Results have been reviewed and recommended by the Audit Committee on 10th November, 2025 and have been approved by the Board of Directors at its meeting held on 10th November, 2025. The Statutory Auditors of the Company have carried out a limited review of Standalone financial results for the quarter and half year ended 30th September, 2025 and expressed unmodified opinion thereon.
- 2 The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 The Company is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 4 The Name of the Company has been changed from **SMS Lifesciences India Limited** to **HALEOS LABS LIMITED** w.e.f. 21.08.2025, pursuant to the approval received from ROC.
- 5 Figures for the previous period have been reclassified / regrouped wherever necessary to conform to current period's classification.

Place: Hyderabad  
Date : 10-11-2025

**For Haleos Labs Limited**

**TVVSN Murthy**  
**Managing Director**  
**DIN: 00465198**



# RAMBABU & CO.,

## CHARTERED ACCOUNTANTS

### Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

Review Report to  
The Board of Directors  
Haleos Labs Limited  
(Formerly known as SMS Lifesciences India Limited)

We have reviewed the accompanying statement of unaudited standalone financial results of Haleos Labs Limited (Formerly known as SMS Lifesciences India Limited) ("the Company"), for the quarter and half year ended 30<sup>th</sup> September 2025 ("the statement"), attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").


This statement which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express conclusion on the Statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements are free of material misstatement. A review of the interim financial information consists of making inquiries primarily of company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad  
Date: 10.11.2025

UDIN: 25026548BMLEWM7583

For Rambabu & Co.,  
Chartered Accountants  
Reg. No. 0029765  
  
G.V. Prasad  
Partner  
M.No. 026548





**HALEOS LABS LIMITED**  
(Formerly known as SMS Lifesciences India Limited)

(CIN: L74930TG2006PLC050223)

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096

Tel:+91-40-6628 8888, Fax:91-40-2355 1401, Email: info@smslife.in

**Consolidated Statement of Unaudited Financial Results for the Quarter and Half Year Ended 30th September, 2025**

(Rs. In Lakhs)

S.No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue From Operations	8,136.76	8,250.46	7,846.19	16,387.23	17,101.01	34,472.35
2	Other Income	42.41	99.59	203.85	137.54	246.42	486.01
3	<b>Total Revenue</b>	<b>8,179.17</b>	<b>8,350.05</b>	<b>8,050.04</b>	<b>16,524.77</b>	<b>17,347.43</b>	<b>34,958.36</b>
4	<b>Expenses</b>						
	(a) Cost of Materials Consumed	3,983.27	2,841.38	3,501.48	6,824.65	7,773.60	14,990.79
	(b) Changes in Inventories	(881.39)	672.57	76.07	(208.82)	135.62	415.21
	(c) Manufacturing Expenses	1,732.08	1,650.46	1,469.39	3,382.54	3,102.98	6,555.05
	(d) Employee Benefits Expense	1,622.84	1,629.17	1,408.77	3,252.01	2,846.68	5,953.78
	(e) Finance Cost	161.53	186.52	213.55	348.05	454.04	871.26
	(f) Depreciation and Amortization Expense	388.63	382.38	376.26	771.01	744.14	1,499.67
	(g) Other Expenses	322.96	285.51	534.12	604.02	755.95	2,053.61
	<b>Total Expenses - (a to g)</b>	<b>7,329.92</b>	<b>7,647.99</b>	<b>7,579.64</b>	<b>14,973.46</b>	<b>15,813.00</b>	<b>32,339.37</b>
5	<b>Profit Before Tax (3-4)</b>	<b>849.25</b>	<b>702.06</b>	<b>470.40</b>	<b>1,551.31</b>	<b>1,534.43</b>	<b>2,618.99</b>
6	<b>Tax Expenses</b>						
	(1) (i) Current Tax	215.00	240.00	238.00	455.00	550.00	900.00
	(ii) Relating to Earlier Year	-	-	-	-	-	(18.86)
	(2) Mat Credit Entitlement	(15.00)	(15.00)	-	(30.00)	-	-
	(2) Deferred Tax	6.72	38.85	(97.63)	45.57	(55.23)	(135.39)
		206.72	263.85	140.37	470.57	494.77	745.75
7	<b>Net Profit / (Loss) for the Period / Year (5-6)</b>	<b>642.53</b>	<b>438.21</b>	<b>330.03</b>	<b>1,080.74</b>	<b>1,039.66</b>	<b>1,873.25</b>
8	<b>Other Comprehensive Income/(Loss) (OCI):</b>						
	Items that will not be reclassified to statement of Profit & Loss						
	Remeasurement of post-employment benefit obligations	5.35	4.91	(19.17)	10.26	(36.73)	17.87
	Income Tax effect on the above	(1.43)	(1.31)	5.53	(2.74)	10.59	(4.78)
		3.92	3.60	(13.64)	7.52	(26.14)	13.09
9	<b>Total comprehensive Income for the period/year (7+8)</b>	<b>646.45</b>	<b>441.81</b>	<b>316.39</b>	<b>1,088.26</b>	<b>1,013.52</b>	<b>1,886.34</b>
10	<b>Profit for the year attributable to:</b>						
	Equity holders of the parent	610.26	415.69	467.26	1,025.95	1,167.07	2,010.91
	Non-controlling interest	32.27	22.52	(137.23)	54.79	(127.41)	(137.66)
11	<b>Total comprehensive income for the year attributable to:</b>						
	Equity holders of the parent	612.96	418.18	454.14	1,031.14	1,141.91	2,019.97
	Non-controlling interest	33.49	23.63	(137.75)	57.12	(128.39)	(133.63)
12	<b>Earning Per Equity Share of Rs.10/- each</b>						
	Basic / Diluted (not annualised)	20.19	13.75	15.46	33.93	38.60	66.51
13	<b>Paid-up equity share capital (Face Value of Rs.10/- each)</b>	<b>302.33</b>	<b>302.33</b>	<b>302.33</b>	<b>302.33</b>	<b>302.33</b>	<b>302.33</b>
14	<b>Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year</b>						19,353.70

For Haleos Labs Limited

TVSN Murthy  
Managing Director  
DIN: 00465198

# Consolidated Statement of Assets and Liabilities as at 30th September, 2025

(Rs.in Lakhs)

Sr. No.	Particulars	As at	As at
		30.09.2025 (Un Audited)	31.03.2025 (Audited)
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-Current Assets</b>		
	(a) Property, Plant and Equipment	22,433.52	23,002.41
	(b) Right-of-use Assets	146.26	177.59
	(c) Capital Work-in-Progress	901.29	39.60
	(d) Intangible Assets	3.98	5.15
	(e) Financial Assets:		
	(i) Investments	3.61	3.61
	(ii) Other Financial Assets	328.77	325.65
	(f) Other Non-Current Assets	703.00	387.73
	<b>Sub Total :Non-Current Assets</b>	<b>24,520.43</b>	<b>23,941.74</b>
<b>2</b>	<b>Current Assets</b>		
	(a) Inventories	7,104.32	6,739.79
	(b) Financial Assets		
	(i) Trade Receivables	6,104.42	6,878.71
	(ii) Cash and Cash Equivalents	53.92	50.29
	(iii) Bank Balances		
	(Other than (ii) above)	103.18	100.52
	(c) Other Current Assets	1,502.40	1,265.31
	(d) Current Tax Assets (Net)	-	22.75
	<b>Sub Total : Current Assets</b>	<b>14,868.24</b>	<b>15,057.37</b>
	<b>TOTAL ASSETS</b>	<b>39,388.67</b>	<b>38,999.11</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Equity:</b>		
	(a) Equity Share Capital	302.33	302.33
	(b) Other Equity	20,339.49	19,353.70
	<b>Equity Attributable to Share Holders of the company</b>	<b>20,641.82</b>	<b>19,656.03</b>
	Non Cotroling Interest	1,605.73	1,548.61
	<b>Sub-Total -Shareholders' funds</b>	<b>22,247.55</b>	<b>21,204.64</b>
	<b>Liabilities:</b>		
<b>2</b>	<b>Non-Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	1,273.41	1,826.79
	(ii) Lease Liabilities	126.00	173.92
	(b) Provisions	546.82	513.25
	(c) Deferred Tax Liabilities (Net)	1,122.07	1,073.76
	<b>Sub-Total -Non-Current Liabilities</b>	<b>3,068.30</b>	<b>3,587.72</b>
<b>3</b>	<b>Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	5,499.51	6,574.67
	(ii) Lease Liabilities	79.73	65.47
	(iii) Trade Payables:		
	(a) Trade Payables - Micro & Small Enterprises	154.18	120.36
	(b) Trade Payables - otherthan Micro & Small Enterprises	5,196.63	5,206.62
	(iv) Other Financial Liabilities	1,181.84	1,301.07
	(b) Provisions	173.48	162.05
	(c) Other Current Liabilities	1,607.48	776.51
	(d) Current Tax Liabilities (Net)	179.97	-
	<b>Sub-Total - Current Liabilities</b>	<b>14,072.82</b>	<b>14,206.76</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>39,388.67</b>	<b>38,999.11</b>

For Haleos Labs Limited

TVVSN Murthy  
Managing Director  
DIN: 00465198



**HALEOS LABS LIMITED**

(Formerly known as SMS Lifesciences India Limited)

Consolidated Statement of Cash Flow for the Half Year Ended 30th September, 2025.

(All amounts in Indian Rupees, unless otherwise stated)

Particulars		For the Half Year ended 30.09.2025	For the Year ended 31.03.2025
<b>A</b>	<b>Cash Flow from Operating Activities</b>		
	Profit Before Income Tax	1,551.31	2,618.99
	<b>Adjustments for:</b>		
	Depreciation and amortisation expense	771.01	1,499.67
	Interest Income classified as Investing Cash Flows	(2.96)	(6.53)
	Allowance for Doubtful Debts	-	505.99
	Interest on Non Current Borrowings	128.15	387.40
	Provision for Employee Benefits	55.26	53.10
	Term Loan Processing Fee	2.07	4.65
	Profit on Sale of Assets	-	(5.94)
	Loss on Sale of Assets	-	2.84
	Interest On Leased Premises	12.84	31.14
		<b>2,517.68</b>	<b>5,091.30</b>
	<b>Change in Operating Assets and Liabilities</b>		
	(Increase)/Decrease in Trade Receivables	774.29	(2,249.66)
	(Increase)/Decrease in Inventories	(364.53)	1,381.26
	Increase/(Decrease) in Trade Payables	25.30	(562.78)
	(Increase)/Decrease in Other Non Current Financial Assets	(3.12)	(11.86)
	(Increase)/Decrease in Other Non Current Asset	(315.27)	(114.39)
	(Increase)/Decrease in Other Current Financial Assets	-	(0.10)
	(Increase)/Decrease in Other Current Asset	(3,411.19)	(3,863.22)
	(Increase) Decrease in Prepaid Taxes	(22.28)	(134.82)
	Increase/(Decrease) in Other Current Financial Liabilities	(4.61)	128.04
	Increase/(Decrease) in Other Current Liabilities	4,005.07	4,591.72
		<b>683.66</b>	<b>(835.81)</b>
	<b>Cash generated from Operations</b>	<b>3,201.34</b>	<b>4,255.49</b>
	Income Taxes Paid	(200.00)	(850.00)
	<b>Net Cash Inflow from Operating Activities "A"</b>	<b>3,001.34</b>	<b>3,405.49</b>
<b>B</b>	<b>Cash flows from Investing Activities</b>		
	Purchase for Property, Plant and Equipment	(1,144.01)	(1,534.86)
	Proceeds from sale of Property, Plant and Equipment	4.45	36.66
	Margin Money Deposits	(0.62)	(7.87)
	Interest Received on Margin Money Deposit	0.91	6.28
	<b>Net Cash Outflow from Investing Activities "B"</b>	<b>(1,139.26)</b>	<b>(1,499.79)</b>
<b>C</b>	<b>Cash flows from Financing Activities</b>		
	Proceeds from Long Term Borrowings	-	35.42
	Repayment of Long Term Borrowings	(774.52)	(1,780.00)
	Proceeds from Short Term Borrowings	(856.08)	370.25
	Repayment of Lease Liability	(33.66)	(61.86)
	Interest paid	(148.84)	(430.82)
	Dividend paid to company's shareholders	(45.35)	(45.35)
	<b>Net Cash (Outflow) from Financing Activities "C"</b>	<b>(1,858.45)</b>	<b>(1,912.36)</b>
	<b>Net Increase (Decrease) in Cash and Cash Equivalents (A+B+C)</b>	<b>3.63</b>	<b>(6.66)</b>
	Cash and Cash Equivalents at the beginning of the Financial Year	50.29	56.95
	<b>Cash and Cash Equivalents at End of the Year</b>	<b>53.92</b>	<b>50.29</b>

For Haleos Labs Limited

**TVVSN Murthy**  
**Managing Director**  
**DIN: 00465198**

**Notes:**

- 1 The above Consolidated Financial Results have been reviewed and recommended by the Audit Committee on 10th November, 2025 and have been approved by the Board of Directors at its meeting held on 10th November, 2025. The Statutory Auditors of the Company have carried out the a limited review of Consolidated financial results for the quarter and half year ended 30th September, 2025 and expressed unmodified opinion thereon.
- 2 The consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- 3 The Consolidated financial results are prepared by applying Ind AS-110 "Consolidated Financial Statements", includes financial results of Mahi Drugs Private Limited, a subsidiary.
- 4 The Consolidated entity is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 5 The Name of the Company has been changed from **SMS Lifesciences India Limited** to **HALEOS LABS LIMITED** w.e.f. 21.08.2025, pursuant to the approval received from ROC.
- 6 Figures for the previous period have been reclassified / regrouped wherever necessary to conform to current period's classification.

**For Haleos Labs Limited**

**TVVSN Murthy**  
**Managing Director**  
**DIN: 00465198**

Place: Hyderabad  
Date : 10-11-2025





**Independent Auditor's Review Report on review of Interim Consolidated Financial Results**

To the Board of Directors of  
**Haleos Labs Limited**  
(Formerly known as **SMS Lifesciences India Limited**)

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial results of **Haleos Labs Limited** (formerly known as **SMS Lifesciences India Limited**) ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 30<sup>th</sup> September, 2025 (the "statement"), being submitted by the parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This statement is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting (Ind AS 34)", prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRI) 2410, *Review of Interim Financial information performed by the Independent Auditor of the Entity*, issued by The Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the result of the following entities

- a. M/s. Haleos Labs Limited (Formerly known as SMS Lifesciences India Limited)
- b. M/s. Mahi Drugs Private Limited



5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.


6. The consolidated unaudited financial results includes the interim financial statements/ financial information of above subsidiary, whose interim financial statements / financial information reflect total revenue of Rs.1,242.89 Lakhs, total net profit after tax of Rs.80.67 Lakhs and total comprehensive income of Rs.83.72 Lakhs for the Quarter ended 30 September, 2025, as considered in the Statement. According to the information and explanations given to us by the Management, the interim financial statements / financial information is not material to the Group. Our conclusion on the Statement is not modified in respect of our reliance on the interim financial statements / financial information certified by the Management.

Place: Hyderabad

Date: 10.11.2025

UDIN: 25026548BMLEWN1625

For Rambabu & Co.,  
Chartered Accountants  
Reg. No.002976S

  
GVI Prasad  
Partner

M. No. 026548





Consolidated Related Party Disclosure for the half year ended March 31, 2025  
[Reg. 23 (9) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015]

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

S.No	Details of the Party (listed entity / subsidiary) entering in to the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee  (Ref - Note 1)	Value of the related party transaction ratified by the audit committee	Value of transaction during reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments					
	Name	PAN (Ref - Note 3)	Name	PAN (Ref - Note 3)	Relationship of the counter party with the listed entity or its subsidiary					Opening Balance	Closing Balance	Nature of indebtedness	Cost	Tenure	Nature (loans/advance/inter-corporate deposit/investment)	Interest rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)	
1	Haleos Labs Limited  (formerly known as SMS Lifesciences India Limited)		Purogene Labs Private Limited (Ref - Note 7)	-	Enterprises over which Directors or their relatives exercise significant influence	Purchases of Goods & Services	4,000.00	-	857.29	119.37	206.93	-	-	-	-	-	-	-	-	
2						Sale of Goods & Services	1,500.00	-	186.22	-	-	-	-	-	-	-	-	-	-	-
3						Rent received	10.00	-	2.12	-	-	-	-	-	-	-	-	-	-	-
4			Mahi Drugs Private Limited	-	Material Subsidiary	Purchases of Goods & Services	5,500.00	-	1,836.95	4,001.80	3,587.95	-	-	-	-	-	-	-	-	-
5						Sale of Goods & Services	2,000.00	-	286.81	-	-	-	-	-	-	-	-	-	-	-
6						Rent received	10.00	-	3.19	-	-	-	-	-	-	-	-	-	-	-
7			SMS Pharmaceuticals Ltd	-	Other Related Party	Purchases of Goods & Services	500.00	-	0.54	-	-	-	-	-	-	-	-	-	-	-
8						Sale of Goods & Services	3,000.00	-	1,204.00	624.41	888.40	-	-	-	-	-	-	-	-	-
9			ChemWerth Inc, USA	-	Other Related Party	Sale of Goods & Services	1,500.00	-	79.77	-100.00	-100.00	-	-	-	-	-	-	-	-	-
10			TVVSN Murthy	-	Key Management Personnel	Remuneration (Ref - Note 6)	-	-	100.16	7.20	7.20	-	-	-	-	-	-	-	-	-
11			T V Praveen	-	Executive Director		-	-	43.42	37.12	6.10	-	-	-	-	-	-	-	-	-
13	Mahi Drugs Private Limited		Purogene Labs Private Limited (Ref - Note 7)	-	Enterprises over which Directors or their relatives exercise significant influence	Purchases of Goods & Services	500.00	-	-	-14.15	-	-	-	-	-	-	-	-	-	
14			ChemWerth Inc, USA	-	Other Related Party	Sale of Goods & Services	3,500.00	-	114.12	-436.82	-347.83	-	-	-	-	-	-	-	-	
16			SMS Pharmaceuticals Ltd	-	Other Related Party	Sale of Goods & Services	500.00	-	143.24	130.19	61.65	-	-	-	-	-	-	-	-	-
Total									4,872.75											

**Note:**

- The value of the related party transactions denotes the amount approved by the Audit Committee/ Board of Directors / Shareholders (wherever applicable) of Company and the subsidiary, as the case may be, for the year 2024-25.
- Purchase / Sale of Goods & Services were approved individually by the Audit Committee/ Board of Directors / Shareholders (wherever applicable) of Company. However, for reporting purpose the same has been clubbed.
- As per the guidance note for disclosure of Related Party Transactions dated 25.04.2022, issued by the Stock Exchanges, since the Company is filing this disclosure in PDF format, the PAN details are not to be included in the disclosure. (XBRL filed separately along with PAN)
- Aforesaid transactions with related parties are in the ordinary course of business and in arm's length basis.
- Sitting fees paid to Independent Directors & Remuneration paid to KMPs are not disclosed pursuant to SEBI (Listing Obligations and Disclosure Requirements) (Third Amendment) Regulations, 2024.
- Remuneration paid to Directors were individual approved by Audit / Board / Shareholders during respective appointment / reappointment.
- Formerly known as "H-Chem (Somanahalli) Private Limited" (Name has changed vide ROC approval w.e.f. 09.02.2024)

**For Haleos Labs Limited**

**TVVSN Murthy**  
Managing Director  
DIN: 00465198